Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xenetic BiosciencesXBIO 78 3-Year RORE % is -26.57 as of Mar. 2026. GuruFocus rates XBIO with a GF Score™ of 78/100 and a GF Value™ of $4.23 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,290 Biotechnology companies, Xenetic Biosciences ranks worse than 65.35% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Xenetic Biosciences's 3-Year RORE % for the quarter that ended in Mar. 2026 was -26.57%.
The industry rank for Xenetic Biosciences's 3-Year RORE % or its related term are showing as below:
XBIO's 3-Year RORE % is ranked worse than 65.35% of 1290
companies
in the Biotechnology industry
Industry Median: -11.54
vs XBIO: -26.57
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Xenetic Biosciences 3-Year RORE % Related Terms
Xenetic Biosciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBIO vs ADIL, PULM, KAPA: 3-Year RORE % Comparison
For the Biotechnology subindustry, Xenetic Biosciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Xenetic Biosciences (XBIO) has a 3-Year RORE % of -26.57 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Xenetic Biosciences and its competitors. According to the industry distribution chart, Xenetic Biosciences ranks #843 out of 1290 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Xenetic Biosciences' 3-Year RORE % too high?
Xenetic Biosciences' current 3-Year RORE % is -26.57. Based on the distribution chart, Xenetic Biosciences ranks #843 out of 1290 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xenetic Biosciences has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' 3-Year RORE % compare to ADIL and PULM?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #843 out of 1290 companies for 3-Year RORE %. This places Xenetic Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current 3-Year RORE % is -26.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $2.48 — trading 41.4% below its estimated fair value. The current 3-Year RORE % is -26.57. Xenetic Biosciences' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current 3-Year RORE % is -26.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $2.48 is trading 41.4% below its estimated GF Value™ of $4.23.
GuruFocus considers Xenetic Biosciences to be Possible Value Trap.
Key valuation signals for XBIO:
3-Year RORE %: -26.57
GF Value™: $4.23 vs. price of $2.48 (41.4% below fair value)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
78GF Score
Get the complete analysis for XBIO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
